Non-infectious Uveitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Non-infectious Uveitis – Drugs In Development, 2024 report and make more profitable business decisions.
Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. Noninfectious uveitis can result from an eye injury or a disease somewhere else in your body. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications.
The Non-infectious Uveitis drugs in development market research report provide comprehensive information on the therapeutics under development for Non-infectious Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-infectious Uveitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Non-infectious Uveitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Non-infectious Uveitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Non-infectious Uveitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Non-infectious Uveitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acelyrin IncActive Biotech AB
Alimera Sciences Inc
Alumis Inc
Avirmax Inc
Cellix Bio Pvt Ltd
Enzo Biochem Inc
HanAll Biopharma Co Ltd
Inflamalps SA
Kiora Pharmaceuticals Inc
Kriya Therapeutics Inc
Novartis AG
ONL Therapeutics Inc
Palatin Technologies Inc
Priovant Therapeutics Inc
Revolo Biotherapeutics Ltd
Ripple therapeutics Corp
Thea Open Innovation SASU
Valitor Inc
Vyome Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Uveitis reports